Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Eisai
Woman and Man Max 99 years
Eisai GmbH
Update Il y a 4 ans
Randomized trial to assess efficacy and safety of an add-on treatment with zonisamide in adults with focal epileptic seizures with or without secondary generalization
The study objective is to assess the efficacy and safety of different doses of an add-on antiepileptic treatment with zonisamide in a larger patient population with focal epilepsy
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eisai Limited
Update Il y a 4 ans
A study done to determine the concentration of the investigational drug, perampanel (E2007) (called, "Study Drug") in the child's blood over a period of time
The primary objective of the study is to evaluate the PK of perampanel during the Maintenance Period of the Core Study following oral suspension administration given as an adjunctive therapy in pediat...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Eisai Medical Research Inc.
Update Il y a 4 ans
EISAI E7389-E044-207 : Essai de phase 2 évaluant l’efficacité et la tolérance de l’eribulin (E7389), chez des patients ayant un sarcome des tissus mous. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
Phase II study of E7389 administered as an IV bolus infusion day 1 and day 8 every 3 weeks in pre-treated patients with advanced and/or metastatic soft tissue sarcoma.
Country
France
organs
Sarcomes
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Eisai Limited
Update Il y a 4 ans
The study being done to see if the Study Drug is safe, tolerable, and can help control seizure in children with epilepsy who are aged 4 to less than 12 years of age and who are already taking seizure medications. The study will also look at pharmacokinetics, which is used to find out the concentration of perampanel in your child’s blood over a period of time
To evaluate the safety and tolerability of perampanel oral suspension when administered as an adjunctive therapy in children (ages 4 to <12 years) with inadequately controlled partial-onset seizures (...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eisai Medical Research Inc
Update Il y a 4 ans
Pharmacokinetics and Safety Study of Rabeprazole Sodium in 12 to 16 Year Old Subjects
To characterize the PK profile of single and repeated doses of rabeprazole sodium in subjects 12 to 16 years of age with a diagnosis of, or symptoms of, GERD.
Country
None
organs
None
Specialty
None
More information
Man Max 99 years
Eisai Limited
Update Il y a 4 ans
Estudio de Fase II multicéntrico, abierto con dos fases para la evaluación preliminar de la eficacia y la seguridad de E 7389 en pacientes con cáncer de próstata avanzado o metastásico refractario a tratamiento hormonal, se realizara una estratificación en relación a la quimioterapia previa A Phase II Multicenter, Open Label, Two-Stage Design Study Evaluating E7389 in Patients with Hormone Refractory Prostate Cancer with Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy
El objetivo primario del estudio es evaluar la eficacia de E7389 en el tratamiento de pacientes con cáncer de próstata hormonorefractario avanzado/metastásico con y sin quimioterapia previa con un age...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Eisai Limited
Update Il y a 4 ans
A clinical trial with a daily dose of E7449, a Poly(ADP-Ribose) Polymerase (PARP) Inhibitor, in patients with Advanced Solid Tumors or with Hematological Tumors and in Combination with Chemotherapy (Temozolomide[TMZ] or with Carboplatin and Paclitaxel) in patients with Advanced Solid Tumors
Primary objective: - Determine maximum tolerated dose (MTD) as single agent, once daily (QD) continuously in 28-day cycles - Determine MTD of E7449, QD for 7 consecutive days in combination with TMZ...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Eisai Ltd
Update Il y a 4 ans
A study conducted in many hospitals, carried out in two groups of patients with advanced skin cancer who know that they are receiving the study medication and have previously received treatment for their advanced skin cancer and the disease has progressed since that treatment
The primary objectives of this study are: • To assess the ORR (complete response + partial response [CR + PR]) of E7080 in subjects with unresectable stage III or stage IV melanoma not harboring the V...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Eisai
Update Il y a 4 ans
Étude E7080-J081-116 : étude de phase 1b évaluant la tolérance et la sécurité d’emploi du lenvatinib en combinaison avec le pembrolizumab chez des patients ayant un carcinome hépatocellulaire. [essai clos aux inclusions]
Le carcinome hépatocellulaire est un cancer primitif du foie qui se développe, dans la grande majorité des cas, à partir des cellules du foie déjà endommagées par une maladie chronique ou une cirrhose...
Country
France
organs
Primitif du foie
Specialty
Thérapies Ciblées
,
Immunothérapie - Vaccinothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Eisai Limited
Update Il y a 4 ans
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Trial to Evaluate the Efficacy and Safety of E2007 in Patients with Painful Diabetic Neuropathy
The primary objective of this study will be to provide evidence of the effectiveness of E2007 for treating the pain of diabetic peripheral neuropathy. (PDN)
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
Next